Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, England.
Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, England.
Cancer Causes Control. 2022 Aug;33(8):1025-1038. doi: 10.1007/s10552-022-01591-w. Epub 2022 Jun 26.
Observational studies and randomized controlled trials (RCTs) have shown an association between vitamin D levels and prostate cancer progression. However, evidence of direct causality is sparse and studies have not examined biological mechanisms, which can provide information on plausibility and strengthen the evidence for causality.
We used the World Cancer Research Fund International/University of Bristol two-stage framework for mechanistic systematic reviews. In stage one, both text mining of published literature and expert opinion identified testosterone as a plausible biological mechanism. In stage two, we performed a systematic review and meta-analysis to assess the evidence from both human and animal studies examining the effect of vitamin D on testosterone, and testosterone on advanced prostate cancer (diagnostic Gleason score of ≥ 8, development of metastasis) or prostate cancer-specific mortality.
A meta-analysis of ten human RCTs showed evidence of an effect of vitamin D on total testosterone (standardised mean difference (SMD) = 0.133, 95% CI = - 0.003-0.269, I = 0.0%, p = 0.056). Five human RCTs showed evidence of an effect of vitamin D on free testosterone (SMD = 0.173, 95% CI = - 0.104-0.450, I = 52.4%, p = 0.220). Three human cohort studies of testosterone on advanced prostate cancer or prostate cancer-specific mortality provided inconsistent results. In one study, higher levels of calculated free testosterone were positively associated with advanced prostate cancer or prostate cancer-specific mortality. In contrast, higher levels of dihydrotestosterone were associated with lowering prostate cancer-specific mortality in another study. No animal studies met the study eligibility criteria.
There is some evidence that vitamin D increases levels of total and free testosterone, although the effect of testosterone levels within the normal range on prostate cancer progression is unclear. The role of testosterone as a mechanism between vitamin D and prostate cancer progression remains inconclusive.
观察性研究和随机对照试验(RCT)表明维生素 D 水平与前列腺癌进展之间存在关联。然而,直接因果关系的证据很少,并且这些研究并未检查生物学机制,而这些机制可以提供有关合理性的信息,并为因果关系提供更强有力的证据。
我们使用世界癌症研究基金会国际/布里斯托大学的两阶段机制系统评价框架。在第一阶段,通过已发表文献的文本挖掘和专家意见,确定了睾丸酮是一种合理的生物学机制。在第二阶段,我们进行了系统评价和荟萃分析,以评估检查维生素 D 对睾丸酮以及睾丸酮对晚期前列腺癌(诊断时的 Gleason 评分≥8 分,发生转移)或前列腺癌特异性死亡率的影响的人体和动物研究的证据。
对 10 项人体 RCT 的荟萃分析表明,维生素 D 对总睾丸酮有影响(标准化均数差(SMD)=0.133,95%CI=-0.003-0.269,I=0.0%,p=0.056)。5 项人体 RCT 表明维生素 D 对游离睾丸酮有影响(SMD=0.173,95%CI=-0.104-0.450,I=52.4%,p=0.220)。关于睾丸酮对晚期前列腺癌或前列腺癌特异性死亡率的三项人体队列研究结果不一致。在一项研究中,计算得出的游离睾丸酮水平较高与晚期前列腺癌或前列腺癌特异性死亡率呈正相关。相比之下,另一项研究中,二氢睾丸酮水平较高与降低前列腺癌特异性死亡率有关。没有符合研究入选标准的动物研究。
有一些证据表明,维生素 D 可增加总睾丸酮和游离睾丸酮的水平,尽管在正常范围内的睾丸酮水平对前列腺癌进展的影响尚不清楚。睾丸酮作为维生素 D 与前列腺癌进展之间关系的机制的作用仍不确定。